Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium

Journal of Medical Microbiology

Volumn 55, Issue 6, 2006, Pages 729-736

  Oyamada, Yoshihiro ^a   Ito, Hideaki ^a   Fujimoto, Kouichi ^a   Asada, Reiko ^a   Niga, Toshiyuki ^a   Okamoto, Ryoichi ^b   Inoue, Matsuhisa ^b   Yamagishi, Jun Ichi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM MUTANT; DRUG EXCRETION; ENTEROCOCCUS FAECIUM; GENE STRUCTURE; GENETIC SELECTION; GYRA GENE; GYRB GENE; MEMBRANE CHANNEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PARE GENE; POINT MUTATION; PRIORITY JOURNAL; QUINOLONE RESISTANCE DETERMINING REGION;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MUTATION;

EID: 33744965372     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46303-0     Document Type: Article

References (31)

1. Aeschlimann, J. R., Dresser, L. D., Kaatz, G. W. & Rybak, M. J. (1999). Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 43, 335-340.
2. Amin, N. E., Jalal, S. & Wretlind, B. (1999). Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother 43, 947-949.
3. Brisse, S., Fluit, A. C., Wagner, U., Heisig, P., Milatovic, D., Verhoef, J., Scheuring, S., Köhrer, K. & Schmitz, F.-J. (1999). Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob Agents Chemother 43, 2513-2516.
4. Celesk, R. A. & Robillard, N. J. (1989). Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 33, 1921-1926.
5. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutations of Staphylococcus aureus. Antimicrob Agents Chemother 39, 1554-1558.
6. Gill, M. J., Brenwald, N. P. & Wise, R. (1999). Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumonias. Antimicrob Agents Chemother 43, 187-189.
7. Gonzalez, M. A., Moranchel, A. H., Duran, S., Pichardo, A., Magana, J. L., Painter, B., Forrest, A. & Drusano, G. L. (1985). Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 28, 235-239.
8. Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 40, 879-885.
9. Hudson, M. C. & Curtiss, R., III (1990). Regulation of expression of Streptococcus mutans genes important to virulence. Infect Immun 58, 464-470.
10. Ito, H., Yoshida, H., Bogaki-Shonai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 38, 2014-2023.
11. Jonas, B. M., Murray, B. E. & Weinstock, G. M. (2001). Characterization of emeA, a norA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Chemother 45, 3574-3579.
12. Kaatz, G. W. & Seo, S. M. (1995). Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 39, 2650-2655.
13. Kanematsu, E., Deguchi, T., Yasuda, M., Kawamura, T., Nishino, Y. & Kawada, Y. (1998). Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerasc IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 42, 433-435.
14. Korten, V., Huang, W. M. & Murray, B. E. (1994). Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 38, 2091-2094.
15. Low, D. L., Keller, N., Barth, A. & Jones, R. (2001). Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32 (Suppl. 2), S133-S145.
16. Moellering, R. C. (1992). Emergence of enterococcus as a significant pathogen. Clin Infect Dis 14, 1173-1176.
17. Morrissey, I. & George, J. (1999). Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother 43, 2579-2585.
18. National Committee for Clinical Laboratory Standards (2003). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standards M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
19. Ng, E. Y. W., Trucksis, M. & Hooper, D. C. (1994). Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 38, 1345-1355.
20. Pan, X.-S. & Fisher, L. M. (1998). DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 42, 2810-2816.
21. Pan, X.-S., Ambler, J., Mehtar, S. & Fisher, L. M. (1996). Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40, 2321-2326.
22. Pan, X.-S., Yague, G. & Fisher, L. M. (2001). Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob Agents Chemother 45, 3140-3147.
23. Piddock, L. J. V. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58 (Suppl. 2), 11-18.
24. Takenouchi, T., Ishii, C., Sugawara, M., Tokue, Y. & Ohya, S. (1995). Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother 39, 1414-1418.
25. Tankovic, J., Mahjoubi, F., Courvalin, P., Duval, J. & Leclercq, R. (1996). Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 40, 2558-2561.
26. Tran, J. H. & Jacoby, G. A. (2002). Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A 99, 5638-5642.
27. Treitman, A. N., Yarnold, P. R., Warren, J. & Noskin, G. A. (2005). Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol 43, 462-463.
28. Yamagishi, J.-I., Kojima, T., Oyamada, Y., Fujimoto, K., Hattori, H., Nakamura, S. & Inoue, M. (1996). Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 40, 1157-1163.
29. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990a). Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34, 1271-1272.
30. Yoshida, H., Bogaki, M., Nakamura, S., Ubukata, K. & Konno, M. (1990b). Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 172, 6942-6949.
31. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. & Nakamura, S. (1991). Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35, 1647-1650.